Fan-Cai Lai

Dr. Fan-Cai Lai


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Experimental Cell Research
Verified
Journal Article
Closed access
MQMingliang Qiu
Mingliang Qiu
GLGuoping Li
Guoping Li
PWPengcheng Wang
Pengcheng Wang
XLXu Li
Xu Li
FLFancai Lai
Fancai Lai
FLFan-Cai Lai
Fan-Cai Lai

29 June 2016 in Journal of Drug Targeting
Verified
Journal Article
Closed access
JLJian-Bo Lin
Jian-Bo Lin
FLFan-Cai Lai
Fan-Cai Lai
FLFan-Cai Lai
Fan-Cai Lai
YTYuan-Rong Tu
Yuan-Rong Tu
MLMin Lin
Min Lin
JLJing-Wei Lin
Jing-Wei Lin
With the advent of molecularly targeted therapy, it is necessary to reconsider the strategy for malignant pleural effusion in non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The aim of this study was to evaluate the efficacy of a two-line sequential treatment strategy in this patient subgroup. First-line treatment was gefitinib (250 mg/day) until disease progression. Second-line treatment was thoracoscopic talc pleurodesis followed by chemotherapy. Primary endpoints were the overall response and progression-free survival rates after first-line treatment, and the overall survival rate after first- and second-line treatment. Secondary endpoints were the success rate of thoracoscopic talc pleurodesis and gefitinib toxicity. Among the 76 patients enrolled, 61 (80%) were female and the median age was 62 years. The overall response rate after first-line treatment was 92.1% and median progression-free survival was 15 months. The success rate for thoracoscopic talc pleurodesis in 33 patients was 94%. Median follow-up was 35 months. Median overall survival was 39 months. The 1- and 3-year overall survival rates were 86.4% and 46.1%, respectively. The two-line sequential treatment strategy enhanced survival. These preliminary findings provide an insight into novel therapeutic models for malignant pleural effusion in NSCLC harbouring EGFR mutations.

1 October 2016 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
JLJian-Bo Lin
Jian-Bo Lin
JCJian-Feng Chen
Jian-Feng Chen
FLFan-Cai Lai
Fan-Cai Lai
XLXu Li
Xu Li
MQMing-Lian Qiu
Ming-Lian Qiu

7 January 2019 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
FLFan-Cai Lai
Fan-Cai Lai
MQMingliang Qiu
Mingliang Qiu
CLChun-Jin Lin
Chun-Jin Lin
XLXu Li
Xu Li
JCJian-Feng Chen
Jian-Feng Chen
BLBo Liu
Bo Liu

5 November 2013
Verified
Journal Article
Closed access
MLMin Lin
Min Lin
YTYuan-Rong Tu
Yuan-Rong Tu
FLFan-Cai Lai
Fan-Cai Lai
XLXu Li
Xu Li
JCJian-Feng Chen
Jian-Feng Chen
FLFan-Cai Lai
Fan-Cai Lai